Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...

Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

With a volume of 12,212,671, the price of MRK is down -1.44% at $88.38. RSI indicators hint that the underlying stock may be ...

Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, ...

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...